Would you agree to chemotherapy if there was no evidence to support its value in treating cancer? Every day, we benefit from medical advances rooted in decades of testing and research. We can measure whether or not people are getting better.
Unfortunately, this is not the case when it comes to mental health and substance use treatment. Until recently, Canada has lacked a large-scale, coordinated effort to monitor how well people are responding to available treatment approaches. In the face of an escalating mental health and substance use crisis, it is vital that treatment providers are able to check in with their clients and routinely measure the progress they are making toward reaching clinical goals and improving quality of life.
In this live virtual conversation, we’ll explore the value of measuring treatment progress and long-term outcomes for people using mental health and substance use services. We’ll discuss how progress-monitoring systems enable timely improvements to treatment. Finally, we’ll share news about exciting work already underway to advance these efforts in Ontario. Questions from the audience are welcome, and time will be allocated for a live Q&A session with our speakers.
Jean Costello, PhD
Director of Evaluation, HRI
Kim Corace, PhD, CPsych
Vice President, Innovation and Transformation, The Royal Ottawa
Associate Professor, University of Ottawa
Past President, Canadian Psychological Association
Rita Notarandrea, MHSc
CEO, Canadian Centre on Substance Use and Addiction
Brian Rush, PhD
HRI Collaborating Scientist
Scientist Emeritus, CAMH
Welcoming comments by our feature sponsor (KPMG):
Mary Jo Fedy
Partner and National Enterprise Leader, KPMG LLP